StockData
Sonoma Pharmaceuticals, Inc. logo

Sonoma Pharmaceuticals, Inc. (SNOA) stock

SNOANasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3082% below fair value
$0.83−0.01 (-0.76%)

Close on Nov 18, 2026Market cap $3.96MP/E –Yield –

Sonoma Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Sonoma Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$1.41M. For fiscal 2026 it was -$2.46M. The highest annual figure on record is -$2.46M in fiscal 2026.

Annual operating income

PeriodPeriod endValueChange
FY2026Mar 31, 2026-$2.46M–
FY2025Mar 31, 2025-$3.71M–
FY2024Mar 31, 2024-$4.70M–
FY2023Mar 31, 2023-$4.57M–
FY2022Mar 31, 2022-$5.89M–
FY2021Mar 31, 2021-$3.45M–
FY2020Mar 31, 2020-$7.39M–
FY2019Mar 31, 2019-$11.26M–
FY2018Mar 31, 2018-$14.19M–
FY2017Mar 31, 2017-$12.97M–
FY2016Mar 31, 2016-$14.71M–
FY2015Mar 31, 2015-$6.66M–
FY2014Mar 31, 2014-$6.05M–
FY2013Mar 31, 2013-$3.37M–
FY2012Mar 31, 2012-$6.47M–
FY2011Mar 31, 2011-$7.51M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026-$40.00K–
Q4 FY2026CQ1 2026Mar 31, 2026-$351.00K–
Q3 FY2026CQ4 2025Dec 31, 2025-$678.00K–
Q2 FY2026CQ3 2025Sep 30, 2025-$337.00K–
Q1 FY2026CQ2 2025Jun 30, 2025-$1.10M–
Q4 FY2025CQ1 2025Mar 31, 2025-$656.00K–
Q3 FY2025CQ4 2024Dec 31, 2024-$1.03M–
Q2 FY2025CQ3 2024Sep 30, 2024-$850.00K–
Q1 FY2025CQ2 2024Jun 30, 2024-$1.17M–
Q4 FY2024CQ1 2024Mar 31, 2024-$1.41M–
Q3 FY2024CQ4 2023Dec 31, 2023-$844.00K–
Q2 FY2024CQ3 2023Sep 30, 2023-$1.21M–
Q1 FY2024CQ2 2023Jun 30, 2023-$1.24M–
Q4 FY2023CQ1 2023Mar 31, 2023-$1.15M–
Q3 FY2023CQ4 2022Dec 31, 2022-$1.83M–
Q2 FY2023CQ3 2022Sep 30, 2022-$731.00K–
Q1 FY2023CQ2 2022Jun 30, 2022-$855.00K–
Q4 FY2022CQ1 2022Mar 31, 2022-$3.06M–
Q3 FY2022CQ4 2021Dec 31, 2021-$958.00K–
Q2 FY2022CQ3 2021Sep 30, 2021-$964.00K-670.4%
Q1 FY2022CQ2 2021Jun 30, 2021-$904.00K–
Q4 FY2021CQ1 2021Mar 31, 2021-$2.81M–
Q3 FY2021CQ4 2020Dec 31, 2020-$138.00K–
Q2 FY2021CQ3 2020Sep 30, 2020$169.00K–
Q1 FY2021CQ2 2020Jun 30, 2020-$665.00K–
Q4 FY2020CQ1 2020Mar 31, 2020-$3.22M–
Q3 FY2020CQ4 2019Dec 31, 2019-$1.11M–
Q2 FY2020CQ3 2019Sep 30, 2019-$1.29M–
Q1 FY2020CQ2 2019Jun 30, 2019-$1.77M–
Q4 FY2019CQ1 2019Mar 31, 2019-$2.70M–
Q3 FY2019CQ4 2018Dec 31, 2018-$2.35M–
Q2 FY2019CQ3 2018Sep 30, 2018-$2.65M–
Q1 FY2019CQ2 2018Jun 30, 2018-$3.55M–
Q4 FY2018CQ1 2018Mar 31, 2018-$4.75M–
Q3 FY2018CQ4 2017Dec 31, 2017-$3.20M–
Q2 FY2018CQ3 2017Sep 30, 2017-$2.86M–
Q1 FY2018CQ2 2017Jun 30, 2017-$3.38M–
Q4 FY2017CQ1 2017Mar 31, 2017-$2.91M–
Q3 FY2017CQ4 2016Dec 31, 2016-$3.57M–
Q2 FY2017CQ3 2016Sep 30, 2016-$2.99M–

More Sonoma Pharmaceuticals figures

See a number that looks wrong?